source
- Novo abandons $285 million partnership with Ascendis for monthly GLP-1 obesity drugNovo Nordisk, which recently rebranded, has terminated a licensing agreement with Ascendis Pharma that was originally valued at up to $285 million. The collaboration, signed in November 2024, was…
- Sionna Therapeutics to lay off 46% of staff after cystic fibrosis trial setbackSionna Therapeutics announced it will cut 46% of its workforce following an unexpected failure in its cystic fibrosis trial. The company, which employed about 59 people, said roughly 27 employees…